Tirzepatide Side Effects: What the Research Reports
Weight Loss & Metabolism Research
In a 72-week, double-blind trial of 2,539 adults with obesity, the most common tirzepatide side effects were gastrointestinal, most of them mild to moderate and clustered in the dose-escalation period (Jastreboff et al., N Engl J Med, 2022). Adverse events led 4.3% to 7.1% of tirzepatide participants to stop treatment, against 2.6% on placebo. This page sets out what the large human trials recorded, how often, how long it lasted, and what the longer-term and animal data add.
Findings
- Across two placebo-controlled trials with 2,519 treated adults, nausea was reported by 25-29% of tirzepatide participants against 8% on placebo, and diarrhea by 19-23% against 8% (FDA prescribing information, 2023).
- Most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time; 1.9% to 4.3% stopped because of gastrointestinal effects, against 0.5% on placebo.
- In 1,032 adults with obesity and prediabetes followed for 176 weeks, the safety profile held and no new safety signals were identified (Jastreboff et al., N Engl J Med, 2025).
- In a 40-week head-to-head trial of 1,879 people with type 2 diabetes, gastrointestinal rates were close to semaglutide’s: nausea 17-22% with tirzepatide against 18% (Frías et al., N Engl J Med, 2021).
View product →What is tirzepatide?
Tirzepatide is a synthetic peptide that activates two gut-hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both hormones are released after a meal and act on insulin release, appetite and stomach emptying, which is why its side-effect profile centres on the digestive system. The efficacy record, including weight change across the large trials, is covered in Tirzepatide Trials: Weight and Diabetes, and how long it stays in circulation is covered in Tirzepatide Half-Life.
What did the large trials report?
The clearest picture comes from the pooled safety data in the US prescribing information, which combined two randomised, double-blind, placebo-controlled trials of adults with overweight or obesity treated for up to 72 weeks. Participants had a mean age of 47 and an average body-mass index of 37.4. Across three dose levels, 4.8% to 6.7% of tirzepatide participants permanently stopped because of adverse reactions, against 3.4% on placebo, and most of those who stopped did so in the first few months because of gastrointestinal effects (FDA prescribing information, 2023).
Common effects
Gastrointestinal effects were reported by 56% of tirzepatide participants at each dose level, against 30% on placebo. The most frequent individual effects were:
| Effect | Tirzepatide | Placebo |
|---|---|---|
| Nausea | 25-29% | 8% |
| Diarrhea | 19-23% | 8% |
| Constipation | 11-17% | 5% |
| Vomiting | 8-13% | 2% |
| Abdominal pain | 9-10% | 5% |
| Indigestion | 9-10% | 4% |
Source: FDA prescribing information (2023), ranges across three dose levels.
Other effects reported in at least 5% of a tirzepatide group were injection-site reactions (6-8% against 2%), fatigue (5-7% against 3%), hypersensitivity reactions such as rash or itching (5% against 3%), belching, hair loss and reflux (each 4-5% against 1-2%), and dizziness (4-5% against 2%). Hair loss tracked weight reduction and was reported more often in women than in men (7.1% against 0.5%); no tirzepatide participant stopped because of it.
Less common effects
The prescribing information lists several effects that were uncommon but tracked closely:
- Gallbladder: gallstones in 1.1% against 1% on placebo, and gallbladder inflammation (cholecystitis) in 0.7% against 0.2%. These events were associated with weight reduction.
- Pancreatitis: adjudicated acute pancreatitis in 0.2% of tirzepatide participants and 0.2% of placebo participants.
- Low blood pressure: 1.6% against 0.1%, more often in people already taking blood-pressure medicines.
- Kidney: acute kidney injury in 0.5% against 0.2%, linked to dehydration from vomiting or diarrhea.
- Low blood sugar: in a trial of people with type 2 diabetes, 4.2% against 1.3% on placebo, and higher when tirzepatide was combined with a sulfonylurea (10.3%) than without (2.1%).
- Heart rate: a mean rise of 1 to 3 beats per minute, with no rise on placebo.
What does the research show about longer-term use?
The longest controlled data come from the participants in the 72-week obesity trial who also had prediabetes. That group, 1,032 adults, stayed on their assigned treatment for 176 weeks, about three and a half years, followed by 17 weeks off treatment. Mean body weight fell 12.3% to 19.7% across the three dose levels against 1.3% on placebo, and 1.3% of tirzepatide participants developed type 2 diabetes against 13.3% on placebo. On safety, the authors reported that, apart from COVID-19, the most common adverse events were gastrointestinal, mostly mild to moderate and concentrated in the first 20 weeks, and that no new safety signals were identified (Jastreboff et al., N Engl J Med, 2025).
What did animal studies find?
In a two-year study in rats, tirzepatide increased the incidence of thyroid C-cell tumours, the cells that produce the hormone calcitonin. In a six-month study in a strain of transgenic mice used for cancer testing, it was not tumour-forming, and it was not genotoxic in a rat bone-marrow test. The prescribing information states that the relevance of the rat finding to humans has not been determined (FDA prescribing information, 2023).
How does tirzepatide compare with semaglutide?
A 40-week, open-label trial randomised 1,879 adults with type 2 diabetes to one of three tirzepatide doses or semaglutide, a GLP-1-only agonist. The most common adverse events in both arms were gastrointestinal and mostly mild to moderate: nausea 17-22% with tirzepatide against 18% with semaglutide, diarrhea 13-16% against 12%, and vomiting 6-10% against 8%. Low blood sugar was reported in 0.2% to 1.7% of tirzepatide participants and 0.4% on semaglutide, and serious adverse events in 5% to 7% against 3% (Frías et al., N Engl J Med, 2021). The efficacy side of that trial is in Tirzepatide vs Semaglutide.
Why research-grade quality and storage matter
The trial figures above describe pharmaceutical material made to a fixed specification. In a laboratory, the reliability of any result depends on knowing that the peptide in the vial is what the label says, at the stated purity, and that it has been kept intact. Every Vistara Labs product is third-party tested, with certificates on the lab reports page. Tirzepatide is supplied as a lyophilised (freeze-dried) powder; handling before and after mixing is covered in How Long Does Tirzepatide Last? and the tirzepatide reconstitution guide. Orders ship from within Canada by Canada Post Xpresspost.
Tirzepatide is supplied for laboratory research use only. The human data above come from clinical trials carried out under medical supervision.
Frequently asked questions
What side effects did tirzepatide trials report most often?
Gastrointestinal effects were the most common. In pooled placebo-controlled trials, nausea was reported by 25-29% of tirzepatide participants against 8% on placebo, diarrhea by 19-23% against 8%, constipation by 11-17% against 5% and vomiting by 8-13% against 2%. Most were mild to moderate.
How long did the gastrointestinal effects last in the trials?
Most nausea, vomiting and diarrhea occurred during the dose-escalation period and decreased over time. Between 1.9% and 4.3% of tirzepatide participants stopped because of gastrointestinal effects, against 0.5% on placebo.
What did the three-year tirzepatide data show about safety?
In 1,032 adults with obesity and prediabetes treated for 176 weeks, the most common adverse events apart from COVID-19 were gastrointestinal, mostly mild to moderate and concentrated in the first 20 weeks, and no new safety signals were identified.
What did animal studies of tirzepatide find?
A two-year rat study found an increase in thyroid C-cell tumours. A six-month study in transgenic mice found no tumour-forming effect, and tirzepatide was not genotoxic. The relevance of the rat finding to humans has not been determined.
Where can I buy tirzepatide in Canada?
Vistara Labs supplies tirzepatide as a lyophilised vial for laboratory research, third-party tested and shipped from within Canada by Canada Post Xpresspost.
Product details from vistaralabs.ca, October 2026. Sources: Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PMID 35658024. Jastreboff AM et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025. PMID 39536238. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021. PMID 34170647. US Food and Drug Administration. Prescribing information for tirzepatide injection (chronic weight management). 2023. FDA label.
More on this: Tirzepatide in Canada: A Researcher’s Buying Guide.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
References
Tirzepatide has one of the largest human trial programmes of any compound in this catalogue, including multiple phase 3 trials.
- Tirzepatide Once Weekly for the Treatment of ObesityRandomised phase 3 trial; 2,539 adults with overweight or obesity without diabetes, 72 weeks.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityRandomised phase 3 withdrawal trial; 670 participants randomised after a 36-week open-label phase.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityRandomised phase 3 trials in adults with obesity and moderate-to-severe obstructive sleep apnoea.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityRandomised phase 3 trial (SUMMIT); 731 patients with obesity-related heart failure with preserved ejection fraction.
- Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysisSystematic review and meta-analysis; 22 trials, 29,023 participants.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
